Cervical Cancer Prevention in the 21st Century

Cost Is Not the Only Issue

Datos Bibliográficos

ID11023948
AutoresDeborah Maine (Deborah Maine is with the Department of International Health, Boston University School of Public Health, and the Center for Global Health and Development, Boston University, Boston, MA. Sarah Hurlburt is with the Center for Global Health and Development, Boston University. At the time of the writing Dana Greeson was with the Department of International Health, Boston University School of Public Health.), Sarah Hurlburt (Deborah Maine is with the Department of International Health, Boston University School of Public Health, and the Center for Global Health and Development, Boston University, Boston, MA. Sarah Hurlburt is with the Center for Global Health and Development, Boston University. At the time of the writing Dana Greeson was with the Department of International Health, Boston University School of Public Health.), Dana Greeson (Deborah Maine is with the Department of International Health, Boston University School of Public Health, and the Center for Global Health and Development, Boston University, Boston, MA. Sarah Hurlburt is with the Center for Global Health and Development, Boston University. At the time of the writing Dana Greeson was with the Department of International Health, Boston University School of Public Health.)
Año2011
Volumen101
Número9
Páginas1549-1555
Fecha de publicación2011-09-01
Peer ReviewedSí
Open AccessNo
TipoARTICLE
RevistaAmerican Journal of Public Health (JOURNAL)
Identificadores de la revistaISSN: 0090-0036 • E-ISSN: 1541-0048
EditorialAmerican Public Health Association (PUBLISHER • US)
DOI10.2105/ajph.2011.300204
PMID21778496
PMCIDPMC3154220
OpenAlexW2106199155
IdiomaEN
Citas recibidas7
Referencias citadas12

The wide publicity related to human papillomavirus (HPV) vaccines has led to a sense that HPV vaccine programs are inevitable in both developed and developing countries, whereas 2 existing methods of screening—visual inspection with ascetic acid (VIA) and DNA testing—have received much less attention. These screening methods detect cervical lesions better than does the Papanicolaou test and allow immediate treatment, minimizing loss to follow-up. These advantages may outweigh the strengths of HPV vaccines. Priority should be given to improving screening coverage with VIA and DNA tests, focusing on women older than 30 years and underserved populations in all countries. This approach will save the lives of millions of women who have already been exposed to HPV and will develop cervical cancer during the next 20 years

Cancer · Cervical cancer · Environmental health · Family medicine · Cervical Cancer and HPV Research · Global Cancer Incidence and Screening · Internal Medicine · Medicine · Viral-associated cancers and disorders